🇺🇸 Arrowhead Pharmaceuticals, Inc.
Forum topic · ARWR · Company page: financials, ownership and filings
Join the discussion on Arrowhead Pharmaceuticals, Inc.
Loading…
Annual report filed (10-K)
Arrowhead Pharmaceuticals, Inc. filed its annual report (Form 10-K) for the year ended 30 September 2026 with the SEC on 12 November 2026.
The financial statements from it are on the company's page.
Results announced on 12 November 2026
Arrowhead Pharmaceuticals, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $38 million (down 85% from a year earlier) and a net loss of $428 million.
Mutual funds: 394 funds hold $4.2 billion
394 mutual funds in 2 countries hold shares of Arrowhead Pharmaceuticals, Inc. worth $4.2 billion, about 36.3% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 222 funds added shares and 181 sold; on balance they sold $10 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.